{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.86","value":"0.1"},{"groupId":"OG001","spread":"0.74","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Lost weight"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.96","value":"0.3"},{"groupId":"OG001","spread":"0.85","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Dry mouth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.61","value":"0.1"},{"groupId":"OG001","spread":"0.65","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Bruises"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.81","value":"0.1"},{"groupId":"OG001","spread":"0.76","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Abdominal discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.93","value":"0.1"},{"groupId":"OG001","spread":"0.72","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Temperature going up and down"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.92","value":"-0.6"},{"groupId":"OG001","spread":"1.07","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Night sweats"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.14","value":"0.4"},{"groupId":"OG001","spread":"0.96","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Skin problems"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.08","value":"0.1"},{"groupId":"OG001","spread":"0.98","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Feel ill"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.01","value":"0.1"},{"groupId":"OG001","spread":"0.91","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Feel lethargic"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.80","value":"0.3"},{"groupId":"OG001","spread":"0.97","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Felt slowed down"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"0.2"},{"groupId":"OG001","spread":"0.90","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Limited in planning activities"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.94","value":"0.0"},{"groupId":"OG001","spread":"0.97","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Worried about health in the future"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.05","value":"0.2"},{"groupId":"OG001","spread":"0.82","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Trouble with chest infections"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.07","value":"0.7"},{"groupId":"OG001","spread":"0.86","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Trouble with other infections"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.22","value":"0.9"},{"groupId":"OG001","spread":"0.97","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Repeated courses of antibiotics"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.96","value":"0.3"},{"groupId":"OG001","spread":"1.00","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Worried about picking up infection"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"description":"The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"MEAN","populationDescription":"ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint. Here, 'n' signifies the number of participants analyzed for the specified symptoms.","reportingStatus":"POSTED","timeFrame":"Baseline to EOT (up to 2 years)","title":"Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment","type":"SECONDARY","unitOfMeasure":"Units on the scale"}